Itacitinib

Drug Profile

Itacitinib

Alternative Names: INCB-039110; INCB39110

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Hodgkin's disease; Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours
  • Discontinued Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 18 Mar 2017 Incyte completes a phase I/II trial in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA
  • 14 Feb 2017 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (Incyte corporation form 10-K, February 2017)
  • 14 Feb 2017 Incyte Corporation plans global pivotal trials for Graft versus host disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top